Does Moderna's mRNA Flu Shot Face a New Challenge From GSK?

Moderna secured FDA approval for mFlusiva, the first mRNA-based seasonal flu vaccine, positioning it to expand beyond COVID-19. Competitive pressure is rising as GSK plans to push its investigational mRNA flu vaccine into late-stage development after positive Phase II data, but Moderna still has a likely 1–2 year runway before GSK’s Phase III efficacy results. The article also notes Moderna shares are up 400% YTD, trading at a premium valuation (24.28x forward 12-month P/S vs 1.94x industry), with 2026–2027 loss-per-share estimates improving over the past month.

Analysis

The near-term market read-through is more important than the actual flu franchise economics: this is a validation event for mRNA as a modality, not yet a material earnings inflection. That tends to help platform-asset multiples first, especially for Moderna and, to a lesser extent, Merck, while the incumbents’ real risk is not immediate share loss but a slowly rising efficacy hurdle that can erode their pricing power over several seasons. For Moderna, the issue is that the stock is already discounting a much cleaner commercialization path; at this valuation, any launch friction matters more than the approval itself.

GSK’s move is strategically interesting because it can be read as both competition and defense. If phase III confirms a broader immune response, large-cap vaccine players may converge on mRNA as the new standard, which compresses the window for Moderna to build a durable lead. But the more immediate winner may be GSK itself: it has a credible incumbent flu franchise, distribution, and now optional mRNA optionality, so it can hedge cannibalization better than a pure-play challenger.

The contrarian risk is that investors overestimate how quickly annual flu adoption changes. Seasonal vaccines are operationally sticky, and physician/payer behavior usually lags clinical superiority by multiple cycles, so the revenue delta is likely measured in seasons, not quarters. The real falsifier for a bullish MRNA view is not one more positive headline; it is weak initial uptake, muted gross-to-net, or a launch that fails to meaningfully improve 2026 flu revenue guidance.

Key Decisions for Investors

• Avoid chasing MRNA after the move; use it as a watchlist name until launch data show real uptake (prescriptions, CDC share, or management flu revenue guide) over the next 1-3 quarters.
• Long GSK / short SNY as a 3-6 month relative-value trade: GSK has mRNA optionality plus an incumbent franchise, while SNY faces more direct defensive pressure if mRNA flu gains credibility.
• If MRNA pulls back on launch skepticism, consider a tactical long only on evidence of early adoption; otherwise fade rallies with 6-12 month put spreads while valuation remains stretched versus sales.
• Long MRK only as a small read-through position, not a standalone catalyst trade; the valuation impact is secondary and depends on oncology execution, not the flu franchise.
• Set an alert on GSK phase III progression and any label differentiation around dual-antigen coverage; positive data would shift the medium-term competitive bar and argue for reducing exposure to legacy flu names.